Lucid Diagnostics Inc
LUCD
Company Profile
Business description
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Contact
360 Madison Avenue
25th Floor
New YorkNY10017
USAT: +1 917 813-1828
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
82
Stocks News & Analysis
stocks
ASX healthcare share remains undervalued ahead of earnings
Margin recovery remains the key driver for this ASX healthcare share.
stocks
Alphabet earnings: Strong AI monetization continues to spearhead results
We maintain our fair value estimate for wide-moat Alphabet.
stocks
AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event
We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,941.50 | 32.70 | -0.36% |
| CAC 40 | 8,372.28 | 73.19 | 0.88% |
| DAX 40 | 25,099.00 | 335.88 | 1.36% |
| Dow JONES (US) | 51,877.74 | 166.09 | 0.32% |
| FTSE 100 | 10,736.23 | 97.06 | 0.91% |
| HKSE | 24,963.23 | 247.58 | -0.98% |
| NASDAQ | 24,932.14 | 205.55 | -0.82% |
| Nikkei 225 | 64,611.15 | 1,811.45 | -2.73% |
| NZX 50 Index | 13,772.29 | 23.02 | -0.17% |
| S&P 500 | 7,399.93 | 8.37 | -0.11% |
| S&P/ASX 200 | 8,772.30 | 23.40 | -0.27% |
| SSE Composite Index | 3,814.20 | 62.58 | -1.61% |